This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bausch (BHC) Up 21.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the first quarter and lowers guidance due to the coronavirus pandemic.
Endo (ENDP) Q1 Earnings Beat on Coronavirus-Led Stockpiling
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic
Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -1.11% and -1.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Bausch Health (BHC) Ahead of Earnings?
by Zacks Equity Research
Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bausch Health (BHC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Starts Dosing With Selinexor for Coronavirus Infection
by Zacks Equity Research
Karyopharm (KPTI) doses the first patient in a phase II study evaluating the low dose of its drug Xpovio (selinexor) to treat hospitalized patients with severe COVID-19 infection. Shares up.
Bausch (BHC) Starts Study on Virazole for Coronavirus Infection
by Zacks Equity Research
Bausch (BHC) begins a clinical study on Virazole in combination with standard-of-care therapy to treat adults with respiratory distress due to COVID-19 in Canada.
Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak
by Zacks Equity Research
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
Why Is Bausch (BHC) Down 46.5% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.
Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.
Should You Buy Bausch Health (BHC) Ahead of Earnings?
by Zacks Equity Research
Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should Value Investors Pick Bausch Health (BHC) Stock Now?
by Zacks Equity Research
Is Bausch Health (BHC) a great pick from the value investor's perspective right now? Read on to know more.
Aerie's (AERI) Application for Roclanda Accepted in Europe
by Zacks Equity Research
European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.
5 Reasons Why Ironwood Stock Should Be in Your Portfolio
by Zacks Equity Research
We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.
Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris
by Zacks Equity Research
Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.
Top Ranked Value Stocks to Buy for December 13
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, December 13th
Are You Looking for a Top Momentum Pick? Why Bausch Health (BHC) is a Great Choice
by Zacks Equity Research
Does Bausch Health (BHC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Is Bausch (BHC) Up 8.2% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Bausch (BHC) Might be Well Poised for a Surge
by Zacks Equity Research
Bausch (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Moving Average Crossover Alert: Bausch Health Companies
by Zacks Equity Research
Bausch Health Companies is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Generic Drugmakers Gain as Price-Fixing Probe Nears an End
by Indrajit Bandyopadhyay
Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.
Top Ranked Value Stocks to Buy for November 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 26th